2014 Drug Approvals: Where We Have Been; Where We Are Going

As we look ahead to the new year, it is worth examining where we have been over the past 14 months. Despite long-ago predictions of interferon-free formulas, of 90% sustained virologic response rates in real-world scenarios, many experts did not realize how quickly these milestones would be achieved.

The end of 2013 ramped up approvals for newer, more effective treatments and 2014 brought about the first combination regimens approved for use without interferon or ribavirin. The timeline below shows just how much has happened in a little more than 1 year.

Additionally, Co-chief Medical Editors, Ira M. Jacobson, MD, and Michael S. Saag, MD, weighed in on the drugs to look for in the coming year. These phase 2 and 3 studies promise to bring about pan-genotypic treatments that will open the doors for difficult-to-treat populations and offer an array of options for health care providers.

After reviewing our timeline, please read Saag’s commentary on the recent approvals and approval process and how the introduction and sale of these drugs will ultimately impact patient care.

“For more details on 2014 FDA approvals in gastroenterology and hepatology, please see our comprehensive coverage here.”

Timeline 1Timeline 2Timeline 3 

Timeline 4Timeline 5Timeline 6

Timeline 7Timeline 8Timeline 9

Timeline 10 

As we look ahead to the new year, it is worth examining where we have been over the past 14 months. Despite long-ago predictions of interferon-free formulas, of 90% sustained virologic response rates in real-world scenarios, many experts did not realize how quickly these milestones would be achieved.

The end of 2013 ramped up approvals for newer, more effective treatments and 2014 brought about the first combination regimens approved for use without interferon or ribavirin. The timeline below shows just how much has happened in a little more than 1 year.

Additionally, Co-chief Medical Editors, Ira M. Jacobson, MD, and Michael S. Saag, MD, weighed in on the drugs to look for in the coming year. These phase 2 and 3 studies promise to bring about pan-genotypic treatments that will open the doors for difficult-to-treat populations and offer an array of options for health care providers.

After reviewing our timeline, please read Saag’s commentary on the recent approvals and approval process and how the introduction and sale of these drugs will ultimately impact patient care.

“For more details on 2014 FDA approvals in gastroenterology and hepatology, please see our comprehensive coverage here.”

Timeline 1Timeline 2Timeline 3 

Timeline 4Timeline 5Timeline 6

Timeline 7Timeline 8Timeline 9

Timeline 10